1. Trial design. Study design schematic of the PF-ILD trial followed by a separate open-label trial (optional): part A (visits 1 through 9 over 52 weeks) and part B (visit 10 through EOT visit over variable period for each patient).
Trial design. Study design schematic of the PF-ILD trial followed by a separate open-label trial (optional): part A (visits 1 through 9 over 52 weeks) and part B (visit 10 through EOT visit over variable period for each patient). EOT, end of treatment; PF-ILD, progressive fibrosing interstitial lung disease; R, randomisation (1:1 ratio for nintedanib:placebo).
Kevin R Flaherty et al. BMJ Open Resp Res 2017;4:e000212
©2017 by British Thoracic Society